Ludwig Institute for Cancer Research Limited

Other

Christophe Lurquin

Pierre Van Der Bruggen

Thierry R Boon-Falleur

Catia Traversari

Etienne De Plaen

Thierry Boon

Benoit Van Den Eynde

Francis Brasseur

Aline Van Pel

Vincent Stroobant

Patrick Chomez

Nathalie Demotte

Rosalie Luiten

Marie-Therese Duffour

Pascal Chaux

Guy R Cornelis

Bernard Lethe

Etienne DePlaen

Charles DeSmet

Erwin Schultz

Guy Warnier

Catie Traversari

Beatrice Gaugler

Pierre Van Der Bruggan

Thiery Boon-Falleur

Guy Cornelius

P Weynants

M Marchand

Marie Marchand

Patrick Weynants

Marie-Thérèse Duffour

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant, recombinant, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Tumor antigens and CTL clones isolated by a novel procedure

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for treating cancer by administering MAGE-derived peptides

The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.

Isolated protein molecules which are members of the MAGE-B family

Isolated nonapeptides which bind to HLA molecules and provoke lysis by

The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MASGE genes.

Isolated nucleic acid molecules which are members of the MAGE-B family

Tumor rejection antigen precursors, tumor rejection antigens and uses

A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.

Method for determining lung adenocarcinomas by assaying for one or more

The invention involves assaying for possible presence of certain cancers, by screening a sample for a member of the MAGE-Xp family of genes. These cancers include testicular seminoma, non-small call lung carcinoma, melanoma, breast cancer, sarcoma, and leukemia.

Method of screening for cancer by detecting messenger RNA for a MAGE-XP

The invention relates to members of the MAGE-Xp family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-Xp family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.

Isolated nucleic acid molecules which are members of the MAGE-Xp family

Growing community of inventors

Brussels, Belgium

Christophe Lurquin